Literature DB >> 31864100

Circulating irisin levels of prenatal and postnatal patients with gestational diabetes mellitus: A systematic review and meta-analysis.

Lingling Cui1, Tianyi Qiao2, Fan Xu2, Zhonglei Li2, Tingting Chen2, Hongli Su3, Guixia Chen3, Li Zhang3, Dongmei Xu3, Xiaofeng Zhang4.   

Abstract

AIMS: At present, there are few studies on the relationship between circulating irisin levels and gestational diabetes mellitus (GDM), and the results are inconsistent. Therefore, this study conducts a systematic review and meta-analysis to comprehensively discuss the role of irisin in the occurrence and development of GDM.
METHODS: We searched the articles on the relationship between GDM and circulating irisin levels up to September 2019, using the CNKI, WANFANG-DATA, PubMed and the Web of Science databases.
RESULTS: Twenty two articles including 3563 participants were selected in the meta-analysis. Meta-analysis found the blood irisin levels for GDM group were significantly lower than that for control group during pregnancy(SMD = -0.88, 95%CI: -1.34, -0.42, P < 0.001). However, there was no significant difference of irisin levels in the postpartum blood and cord blood between the two groups (SMD = -1.44, 95 %CI: -3.79, 0.92, P = 0.23; SMD = -0.17, 95 %CI: -0.59, 0.25, P = 0.42, respectively).
CONCLUSIONS: Compared with the control group, irisin levels in the GDM group during pregnancy are lower. However, it is no significant difference of irisin levels in the postpartum blood and cord blood. Irisin may play an important role in the occurrence and development of GDM, which needs further research to demonstrate.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GDM; Irisin; Meta-analysis; Postnatal; Prenatal

Mesh:

Substances:

Year:  2019        PMID: 31864100     DOI: 10.1016/j.cyto.2019.154924

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

2.  Altered features of neurotransmitters: NPY, α-MSH, and AgRP in type 2 diabetic patients with hypertension.

Authors:  Baoxin Li; Shuang Ma; Shuqin Guo; Na Li; Dandan Liu; He Wang; Na Zhai; Yunliang Zhang
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

Review 3.  The Role of the Adipokines in the Most Common Gestational Complications.

Authors:  Paweł Gutaj; Rafał Sibiak; Maurycy Jankowski; Karina Awdi; Rut Bryl; Paul Mozdziak; Bartosz Kempisty; Ewa Wender-Ozegowska
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

Review 4.  Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus.

Authors:  Monika Ruszała; Magdalena Niebrzydowska; Aleksandra Pilszyk; Żaneta Kimber-Trojnar; Marcin Trojnar; Bożena Leszczyńska-Gorzelak
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

Review 5.  The Impact of Gestational Diabetes Mellitus on Human Milk Metabolic Hormones: A Systematic Review.

Authors:  Majed A Suwaydi; Xiaojie Zhou; Sharon L Perrella; Mary E Wlodek; Ching Tat Lai; Zoya Gridneva; Donna T Geddes
Journal:  Nutrients       Date:  2022-09-01       Impact factor: 6.706

Review 6.  Progress and Challenges in the Biology of FNDC5 and Irisin.

Authors:  Steffen Maak; Frode Norheim; Christian A Drevon; Harold P Erickson
Journal:  Endocr Rev       Date:  2021-07-16       Impact factor: 19.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.